Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation

Bone Marrow Transplant. 2000 Sep;26(6):677-9. doi: 10.1038/sj.bmt.1702567.

Abstract

Two patients with disseminated mantle-cell lymphoma relapsed 24 and 13 months, respectively, after high-dose chemotherapy and autologous stem cell transplantation (autoSCT). Both patients had an HLA-identical sibling and received an allogeneic stem cell transplant (alloSCT) 32 and 18 months after autologous transplant, after conditioning with fractionated 12 Gy total body irradiation plus cyclophosphamide 120 mg/kg. They are both alive and in complete remission 24 months after transplant. Both patients have developed chronic graft-versus-host disease and their Karnofsky performance status is 90%. AlloSCT may offer a useful approach in a subgroup of patients with mantle-cell lymphoma who have relapsed after autologous transplantation.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Carmustine
  • Cyclophosphamide
  • Cytarabine
  • Etoposide
  • Female
  • Granulocyte Colony-Stimulating Factor
  • Hematopoietic Stem Cell Mobilization / methods
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lymphoma, Mantle-Cell / therapy*
  • Male
  • Melphalan
  • Middle Aged
  • Transplantation Conditioning / methods
  • Transplantation, Homologous
  • Whole-Body Irradiation

Substances

  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Etoposide
  • Cyclophosphamide
  • Melphalan
  • Carmustine

Supplementary concepts

  • BEAM regimen